C4 Therapeutics to present biomarker data on cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on cemsidomide’s immunomodulatory effects with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at IMS.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.